Switching From SSRI to Desvenlafaxine on Cognitive Functioning

UnknownOBSERVATIONAL
Enrollment

36

Participants

Timeline

Start Date

April 3, 2018

Primary Completion Date

June 3, 2019

Study Completion Date

June 3, 2019

Conditions
Major Depressive Disorder
Interventions
DRUG

Desvenlafaxine

Patients included in the study will receive antidepressant treatment with desvenlafaxine. The switch from SSRI to desvenlafaxine will coincide with the baseline visit (Visit 0). The dose of desvenlafaxine will be established based on clinical judgment. As the approach will be naturalistic, the inclusion in this study will not influence the clinical choice, hence changes in the pharmacological strategy will be permitted.

Trial Locations (1)

08208

RECRUITING

Corporació Sanitària Parc Taulí, Sabadell

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Corporacion Parc Tauli

OTHER